Opendata, web and dolomites

HOPE SIGNED

automatic detection and localization of High frequency Oscillation in Paediatric Epilepsy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HOPE project word cloud

Explore the words cloud of the HOPE project. It provides you a very rough idea of what is the project "HOPE" about.

responsible    25    noise    oscillations    correctly    meg    academic    industrial    investigations    invasive    electrodes    epileptogenicity    proven    resistant    paradigmatic    tissue    generating    date    found    epileptic    characterise    propagated    shown    molecular    hope    emerged    relevance    ez    approximately    invasiveness    frequency    originated    clinical    accuracy    self    eeg    diagnostic    sampling    last    quantify    chance    recordings    platform    continuing    improves    hz    limitations    tackling    surgery    recognition    modulation    hardware    computational    outcome    mainly    benefit    epileptogenic    close    intracranial    outcomes    detection    diagnosis    record    medically    ieeg    neurofeedback    attacks    drugs    bci    monitoring    refractory    continuous    surgical    biomarker    interaction    mre    area    hfos    seizures    software    resection    placed    spatial    patients    remove    limited    postsurgical    detect    electroencephalogram    tests    few    zone    epilepsy    signal    mechanisms   

Project "HOPE" data sheet

The following table provides information about the project.

Coordinator
ASTON UNIVERSITY 

Organization address
address: ASTON TRIANGLE
city: BIRMINGHAM
postcode: B4 7ET
website: www.aston.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 1˙214˙400 €
 EC max contribution 1˙214˙400 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2018
 Funding Scheme MSCA-RISE
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASTON UNIVERSITY UK (BIRMINGHAM) coordinator 276˙000.00
2    AAI SCIENTIFIC CULTURAL SERVICES LIMITED CY (LEFKOSIA) participant 193˙200.00
3    ARISTOTELIO PANEPISTIMIO THESSALONIKIS EL (THESSALONIKI) participant 165˙600.00
4    UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA IT (ROMA) participant 128˙800.00
5    BRAINSIGNS SRL IT (ROMA) participant 110˙400.00
6    G.TEC MEDICAL ENGINEERING GMBH AT (SCHIEDLBERG) participant 105˙800.00
7    YORK INSTRUMENTS LTD UK (YORK) participant 82˙800.00
8    POLYTECHNEIO KRITIS EL (CHANIA) participant 73˙600.00
9    INSTITOYTO BIOIATPIKHE TEXNOLOGIAS EL (PATRAS) participant 59˙800.00
10    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 13˙800.00
11    STICHTING VUMC NL (AMSTERDAM) participant 4˙600.00
12    BIRMINGHAM WOMENS AND CHILDRENS NHS FOUNDATION TRUST UK (BIRMINGHAM) participant 0.00
13    CHILDREN'S HOSPITAL CORPORATION US (BOSTON) partner 0.00

Map

 Project objective

In spite of the continuous development of new drugs that target molecular mechanisms responsible for generating epileptic seizures, approximately 25% of the patients with epilepsy are proven medically resistant. These patients should be evaluated for surgery to remove the area responsible for generating the attacks referred to as the epileptogenic zone (EZ). Surgical outcomes strongly depend on the accuracy of the recognition of the EZ, which is currently identified using a potential range of diagnostic tests. In such cases, long-term intracranial electroencephalogram (iEEG) monitoring is used to correctly characterise the seizures and establish the surgical approach. iEEG monitoring has however its limitations, which are mainly found in its invasiveness, cost and the limited spatial sampling - i.e. the chance to record activity propagated from other close areas and not originated where electrodes are placed. To date, this results in a significant number of patients continuing to experience postsurgical seizures. During the last few years, high-frequency oscillations (HFOs above 80 Hz) have emerged as a new promising biomarker in pre-surgical diagnosis of epileptogenicity. Indeed, recent studies have shown that the resection of the tissue generating HFOs improves surgical outcome in patients with medically refractory epilepsy (MRE). HOPE aims to facilitate the interaction between academic, clinical industrial partners to produce a step-change in our ability to detect and quantify HFOs using non-invasive investigations like EEG and MEG, tackling the existing limitations at computational, hardware and software level. As the HFOs are a paradigmatic case for signal detection in low signal/noise condition, the technology will also benefit research in neurofeedback and BCI recordings and allow is to develop and evaluate a neurofeedback platform for the self-modulation of HFOs, and it’s relevance to clinical management of MRE.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HOPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HOPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

ROVER (2020)

RELIABLE TECHNOLOGIES AND MODELS FOR VERIFIED WIRELESS BODY-CENTRIC TRANSMISSION AND LOCALIZATION

Read More  

MAIL (2019)

Identifying Marginal Lands in Europe and strengthening their contribution potentialities in a CO2sequestration strategy

Read More  

MEGA (2019)

Heavy metal free emitters for new-generation light sources

Read More